Baseline α–synuclein Seeding Activity and Disease Progression Code

Output Details

Project Title: Baseline α-synuclein seeding activity and Parkinson’s disease progression in the Parkinson's Progression Markers Initiative cohort Project Overview: Included in this repository is the SAS code used analyze longitudinal clinical and a-synuclein seed amplification assay data from the Parkinson's Progression Markers Initiative (PPMI) and the R code used to create figures. Dependencies: The data required to run this code can be found in the PPMI Database ([www.ppmi-info.org/access-data-specimens/download-data](http://www.ppmi-info.org/access-data-specimens/download-data); RRID:SCR00_6431). After downloading and curating the data from PPMI, simply update the working directory and file paths to run this code. The following R packages are required to run this code: dplyr, readxl, tableone, writexl, tidyr, VennDiagram, grid, lme4, lmerTest, ggplot2, sjPlot, broom.mixed, patchwork, ggpubr, RColorBrewer, vcd. Installation: All dependencies will be automatically installed when running this code. Citation: cff-version 1.2.0 - Type: Software - Authors: - Jackson G. Schumacher - Email: [[email protected]](mailto:[email protected]) - Affiliation: >- Aligning Science Across Parkinson's and Massachusetts General Hospital - ORCID: [https://orcid.org/0009-0000-4227-4710](https://orcid.org/0009-0000-4227-4710) - Xinyuan Zhang - Email: [[email protected]](mailto:[email protected]) - Affiliation: Harvard Medical School - ORCID: [https://orcid.org/0000-0002-2974-8392](https://orcid.org/0000-0002-2974-8392) - License: CC-BY-4.0 Acknowledgements: This research was funded in part by Aligning Science Across Parkinson's No. ASAP-237603 through the Michael J. Fox Foundation for Parkinson's Research (MJFF) and by the National Institute of Health through the National Institute of Neurological Disorders and Stroke grants R01NS102735 and 5R01NS126260. The authors would like to thank PPMI – a public-private partnership – funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.
Identifier (DOI)
10.5281/zenodo.14902493
Tags
  • Cognitive decline
  • DAT imaging
  • Epidemiology
  • Motor symptoms
  • Non-motor symptoms
  • PD progression

Meet the Authors

  • Jackson Schumacher

    Project Manager: Team Chen

    Massachusetts General Hospital

  • User avatar fallback logo

    Xinyuan Zhang

  • User avatar fallback logo

    Eric Macklin

    Key Personnel: Team Chen

    Massachusetts General Hospital

  • User avatar fallback logo

    Jian Wang, PhD

    Key Personnel: Team Chen

    The University of Texas MD Anderson Cancer Center

  • User avatar fallback logo

    Marianna Cortese

  • User avatar fallback logo

    Xuehong Zhang

  • Xiqun Chen

    Lead PI (Core Leadership): Team Chen

    Massachusetts General Hospital